You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCefotaxime
Accession NumberDB00493  (APRD00854)
TypeSmall Molecule
GroupsApproved
Description

Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis).

Structure
Thumb
Synonyms
(6R,7R,Z)-3-(Acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-3-(Acetoxymethyl)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-3-Acetoxymethyl-7-{2-(2-amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefotaxim
Cefotaxima
Céfotaxime
Cefotaximum
Cephotaxime
External Identifiers
  • CTX
  • HR 756
  • RU 24662
  • RU 24756
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cefotaxime for Injection USPpowder for solution2 gintramuscular; intravenousNovopharm LimitedNot applicableNot applicableCanada
Cefotaxime for Injection USPpowder for solution1 gintramuscular; intravenousNovopharm LimitedNot applicableNot applicableCanada
Cefotaxime for Injection USPpowder for solution500 mgintramuscular; intravenousNovopharm LimitedNot applicableNot applicableCanada
Cefotaxime Sodium for Injection BPpowder for solution1 gintramuscular; intravenousAurobindo Pharma Limited (Unit Vi)Not applicableNot applicableCanada
Cefotaxime Sodium for Injection BPpowder for solution0.5 gintramuscular; intravenousAurobindo Pharma Limited (Unit Vi)Not applicableNot applicableCanada
Cefotaxime Sodium for Injection BPpowder for solution2 gintramuscular; intravenousAurobindo Pharma Limited (Unit Vi)Not applicableNot applicableCanada
Cefotaxime Sodium for Injection, BPpowder for solution250 mgintramuscular; intravenousHospira Healthcare CorporationNot applicableNot applicableCanada
Cefotaxime Sodium for Injection, BPpowder for solution2 gintramuscular; intravenousSterimax Inc2015-03-12Not applicableCanada
Cefotaxime Sodium for Injection, BPpowder for solution1 gintramuscular; intravenousSterimax Inc2015-03-12Not applicableCanada
Cefotaxime Sodium for Injection, BPpowder for solution2.0 gintramuscular; intravenousHospira Healthcare Corporation2010-07-06Not applicableCanada
Cefotaxime Sodium for Injection, BPpowder for solution500 mgintramuscular; intravenousSterimax IncNot applicableNot applicableCanada
Cefotaxime Sodium for Injection, BPpowder for solution1.0 gintramuscular; intravenousHospira Healthcare Corporation2010-09-16Not applicableCanada
Cefotaxime Sodium for Injection, BPpowder for solution500 mgintramuscular; intravenousHospira Healthcare Corporation2010-07-07Not applicableCanada
Claforaninjection500 mg/1intramuscular; intravenousSanofi Aventis U.S. Llc1981-03-11Not applicableUs
Claforaninjection1 g/gintramuscular; intravenousGeneral Injectables & Vaccines, Inc2012-06-07Not applicableUs
Claforaninjection2 g/50mLintramuscular; intravenousSanofi Aventis U.S. Llc1985-05-20Not applicableUs
Claforaninjection1 g/50mLintramuscular; intravenousSanofi Aventis U.S. Llc1985-05-20Not applicableUs
Claforaninjection10 g/1intramuscular; intravenousSanofi Aventis U.S. Llc1981-03-11Not applicableUs
Claforaninjection2 g/1intramuscular; intravenousSanofi Aventis U.S. Llc1981-03-11Not applicableUs
Claforaninjection1 g/1intramuscular; intravenousSanofi Aventis U.S. Llc1981-03-11Not applicableUs
Claforan - Pws Inj 1.0g/vialpowder for solution1 gintramuscular; intravenousSanofi Aventis Canada Inc2003-10-10Not applicableCanada
Claforan - Pws Inj 2.0g/vialpowder for solution2 gintramuscular; intravenousSanofi Aventis Canada Inc2003-08-11Not applicableCanada
Claforan - Pws Inj 500mg/vialpowder for solution500 mgintramuscular; intravenousSanofi Aventis Canada Inc2003-12-192012-12-31Canada
Claforan 0.5gm/vialpowder for solution500 mgintramuscular; intravenousRoussel Canada Inc.1982-12-311997-08-05Canada
Claforan 1gm/vialpowder for solution1 gintramuscular; intravenousRoussel Canada Inc.1982-12-311996-09-09Canada
Claforan 2gm/vialpowder for solution2 gintramuscular; intravenousRoussel Canada Inc.1982-12-311996-09-09Canada
Claforan Add-vantage Vials 1gm/vialpowder for solution1 gintravenousHoechst Roussel Canada Inc.1998-08-282000-07-28Canada
Claforan Inj 1gm/add-vantage Vialpowder for solution1 gintravenousRoussel Canada Inc.1989-12-311999-08-11Canada
Claforan Pws Inj 1.0gm/vialpowder for solution1 gintramuscular; intravenousHoechst Roussel Canada Inc.1982-12-312005-08-01Canada
Claforan Pws Inj 2.0gm/vialpowder for solution2 gintramuscular; intravenousHoechst Roussel Canada Inc.1994-12-312005-08-01Canada
Claforan Pws Inj 500mg/vialpowder for solution500 mgintramuscular; intravenousHoechst Roussel Canada Inc.1982-12-312005-08-01Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cefotaximeinjection, powder, for solution2 g/1intravenousHospira, Inc.2016-02-19Not applicableUs
Cefotaximeinjection, powder, for solution1 g/mLintramuscular; intravenousWockhardt Limited2006-08-29Not applicableUs
Cefotaximeinjection, powder, for solution1 g/1intravenousHospira, Inc.2016-02-19Not applicableUs
Cefotaximeinjection, powder, for solution2 g/mLintramuscular; intravenousWockhardt Limited2008-06-20Not applicableUs
Cefotaximeinjection, powder, for solution2 g/1intramuscular; intravenousLupin Pharmaceuticals, Inc.2005-05-27Not applicableUs
Cefotaximeinjection, powder, for solution500 mg/mLintramuscular; intravenousWockhardt Limited2008-06-20Not applicableUs
Cefotaximeinjection, powder, for solution1 g/1intramuscular; intravenousLupin Pharmaceuticals, Inc.2005-05-27Not applicableUs
Cefotaximeinjection10 g/1intravenousWest ward Pharmaceutical Corp2002-11-20Not applicableUs
Cefotaximeinjection, powder, for solution500 mg/1intramuscular; intravenousLupin Pharmaceuticals, Inc.2005-05-27Not applicableUs
Cefotaximeinjection, powder, for solution2 g/1intramuscular; intravenousWest ward Pharmaceutical Corp2002-11-20Not applicableUs
Cefotaximeinjection, powder, for solution1 g/1intramuscular; intravenousWockhardt USA LLC.2006-08-29Not applicableUs
Cefotaximeinjection, powder, for solution1 g/1intramuscular; intravenousWest ward Pharmaceutical Corp2002-11-20Not applicableUs
Cefotaximeinjection, powder, for solution2 g/1intramuscular; intravenousWockhardt USA LLC.2008-06-20Not applicableUs
Cefotaximeinjection, powder, for solution500 mg/1intramuscular; intravenousWest ward Pharmaceutical Corp2002-11-20Not applicableUs
Cefotaximeinjection, powder, for solution500 mg/1intramuscular; intravenousWockhardt USA LLC.2008-06-20Not applicableUs
Claforaninjection1 g/1intramuscular; intravenousSanofi Aventis U.S. Llc1987-01-13Not applicableUs
Claforaninjection2 g/1intramuscular; intravenousSanofi Aventis U.S. Llc1987-01-13Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
RantaksymRanbaxy
RaximRanbaxy
SpinocefAbbott
SporimPharmacare
TalcefIpca
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Cefotaxime sodium
Thumb
  • InChI Key: AZZMGZXNTDTSME-UAGKDTLGSA-M
  • Monoisotopic Mass: 477.038883946
  • Average Mass: 477.447
DBSALT000547
Categories
UNIIN2GI8B1GK7
CAS number63527-52-6
WeightAverage: 455.465
Monoisotopic: 455.056939303
Chemical FormulaC16H17N5O7S2
InChI KeyInChIKey=GPRBEKHLDVQUJE-QSWIMTSFSA-N
InChI
InChI=1S/C16H17N5O7S2/c1-6(22)28-3-7-4-29-14-10(13(24)21(14)11(7)15(25)26)19-12(23)9(20-27-2)8-5-30-16(17)18-8/h5,10,14H,3-4H2,1-2H3,(H2,17,18)(H,19,23)(H,25,26)/b20-9-/t10-,14-/m1/s1
IUPAC Name
(6R,7R)-3-[(acetyloxy)methyl]-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
SMILES
[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[[email protected]]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as cephalosporins. These are compounds containing a 1,2-thiazine fused to a 2-azetidinone to for a oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid moiety or a derivative thereof.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassLactams
Sub ClassBeta lactams
Direct ParentCephalosporins
Alternative Parents
Substituents
  • Cephalosporin
  • N-acyl-alpha amino acid or derivatives
  • Alpha-amino acid or derivatives
  • 2,4-disubstituted 1,3-thiazole
  • Primary aromatic amine
  • Meta-thiazine
  • Heteroaromatic compound
  • Acetate salt
  • Thiazole
  • Tertiary carboxylic acid amide
  • Azole
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Oxime ether
  • Carboxylic acid ester
  • Carboxamide group
  • Azetidine
  • Azacycle
  • Dialkylthioether
  • Hemithioaminal
  • Thioether
  • Monocarboxylic acid or derivatives
  • Enamine
  • Carboxylic acid
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationUsed to treat gonorrhoea, meningitis, and severe infections including infections of the kidney (pyelonephritis) and urinary system. Also used before an operation to prevent infection after surgery.
PharmacodynamicsCefotaxime is a third generation intravenous cephalosporin antibiotic. It has broad spectrum activity against Gram positive and Gram negative bacteria. It does not have activity against Pseudomonas aeruginosa. Cefotaxime works by inhibiting bacterial cell wall biosynthesis. A positive feature of cefotaxime is that it display a resistance to penicillinases and is useful to treat infections that are resistant to penicillin derivatives.
Mechanism of actionThe bactericidal activity of cefotaxime results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Cefotaxime shows high affinity for penicillin-binding proteins in the cell wall including PBP Ib and PBP III.
Related Articles
AbsorptionRapidly absorbed following intramuscular injection.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Approximately 20-36% of an intravenously administered dose of 14C-cefotaxime is excreted by the kidney as unchanged cefotaxime and 15-25% as the desacetyl derivative, the major metabolite. The desacetyl metabolite has been shown to contribute to the bactericidal activity. Two other urinary metabolites (M2 and M3) account for about 20-25%. They lack bactericidal activity.

SubstrateEnzymesProduct
Cefotaxime
Not Available
Desacetyl-cefotaximeDetails
Route of eliminationApproximately 20-36% of an intravenously administered dose of 14C-cefotaxime is excreted by the kidney as unchanged cefotaxime and 15-25% as the desacetyl derivative, the major metabolite.
Half lifeApproximately 1 hour.
ClearanceNot Available
ToxicityAdverse effects following overdosage include nausea, vomiting, epigastric distress, diarrhea, and convulsions. Oral rat LD50 is over 20,000 mg/kg while intravenous rat LD50 is over 7,000 mg/kg.
Affected organisms
  • Enteric bacteria and other eubacteria
  • Neisseria meningitidis
  • Haemophilus influenzae
  • Neisseria gonorrhoeae
  • Escherichia coli
  • Salmonella typhi
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.6285
Blood Brain Barrier-0.9877
Caco-2 permeable-0.761
P-glycoprotein substrateSubstrate0.7271
P-glycoprotein inhibitor INon-inhibitor0.9091
P-glycoprotein inhibitor IIInhibitor0.5397
Renal organic cation transporterNon-inhibitor0.8465
CYP450 2C9 substrateNon-substrate0.8527
CYP450 2D6 substrateNon-substrate0.8222
CYP450 3A4 substrateNon-substrate0.5
CYP450 1A2 substrateNon-inhibitor0.8014
CYP450 2C9 inhibitorNon-inhibitor0.812
CYP450 2D6 inhibitorNon-inhibitor0.8945
CYP450 2C19 inhibitorNon-inhibitor0.7749
CYP450 3A4 inhibitorNon-inhibitor0.7505
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9174
Ames testNon AMES toxic0.8513
CarcinogenicityNon-carcinogens0.8653
BiodegradationNot ready biodegradable0.9931
Rat acute toxicity1.7964 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9873
hERG inhibition (predictor II)Non-inhibitor0.8723
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • App pharmaceuticals llc
  • Hikma farmaceutica lda
  • Wockhardt ltd
  • B braun medical inc
  • Aurobindo pharma ltd
  • Cephazone pharma llc
  • Lupin ltd
  • Orchid healthcare
  • Sanofi aventis us llc
Packagers
Dosage forms
FormRouteStrength
Injectionintravenous10 g/1
Injection, powder, for solutionintramuscular; intravenous1 g/1
Injection, powder, for solutionintramuscular; intravenous1 g/mL
Injection, powder, for solutionintramuscular; intravenous2 g/mL
Injection, powder, for solutionintramuscular; intravenous2 g/1
Injection, powder, for solutionintramuscular; intravenous500 mg/1
Injection, powder, for solutionintramuscular; intravenous500 mg/mL
Injection, powder, for solutionintravenous1 g/1
Injection, powder, for solutionintravenous2 g/1
Powder for solutionintramuscular; intravenous0.5 g
Powder for solutionintramuscular; intravenous1.0 g
Powder for solutionintramuscular; intravenous2.0 g
Powder for solutionintramuscular; intravenous250 mg
Powder for solutionintramuscular; intravenous500 mg
Injectionintramuscular; intravenous1 g/g
Injectionintramuscular; intravenous1 g/1
Injectionintramuscular; intravenous1 g/50mL
Injectionintramuscular; intravenous10 g/1
Injectionintramuscular; intravenous2 g/1
Injectionintramuscular; intravenous2 g/50mL
Injectionintramuscular; intravenous500 mg/1
Powder for solutionintramuscular; intravenous1 g
Powder for solutionintramuscular; intravenous2 g
Powder for solutionintravenous1 g
Prices
Unit descriptionCostUnit
Cefotaxime sodium 10 gm vial31.43USD vial
Claforan 10 gm vial28.64USD vial
Claforan 2 g/vial20.72USD vial
Claforan 2 gm infusion btl11.76USD each
Claforan 1 g/vial10.36USD vial
Claforan 500 mg/vial6.76USD vial
Cefotaxime sodium 2 gm vial6.48USD vial
Claforan 1 gm infusion btl6.08USD each
Claforan 2 gm vial5.74USD vial
Cefotaxime sodium 1 gm vial3.24USD vial
Claforan 1 gm vial2.12USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySolubleNot Available
logP-0.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.146 mg/mLALOGPS
logP0.14ALOGPS
logP-1.4ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)3.18ChemAxon
pKa (Strongest Basic)4.15ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area173.51 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity105.11 m3·mol-1ChemAxon
Polarizability41.78 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Ingolf Macher, Gerhard Widschwenter, “Production of cefotaxime and new sodium salts.” U.S. Patent US5831086, issued May, 1992.

US5831086
General ReferencesNot Available
External Links
ATC CodesJ01DD01J01DD51
AHFS Codes
  • 08:12.06.12
PDB EntriesNot Available
FDA labelDownload (241 KB)
MSDSDownload (38.9 KB)
Interactions
Drug Interactions
Drug
AcenocoumarolCefotaxime may increase the anticoagulant activities of Acenocoumarol.
AmikacinCefotaxime may increase the nephrotoxic activities of Amikacin.
ArbekacinCefotaxime may increase the nephrotoxic activities of Arbekacin.
DicoumarolCefotaxime may increase the anticoagulant activities of Dicoumarol.
FramycetinCefotaxime may increase the nephrotoxic activities of Framycetin.
GentamicinCefotaxime may increase the nephrotoxic activities of Gentamicin.
KanamycinCefotaxime may increase the nephrotoxic activities of Kanamycin.
NeomycinCefotaxime may increase the nephrotoxic activities of Neomycin.
NetilmicinCefotaxime may increase the nephrotoxic activities of Netilmicin.
Picosulfuric acidThe therapeutic efficacy of Sodium picosulfate can be decreased when used in combination with Cefotaxime.
ProbenecidThe serum concentration of Cefotaxime can be increased when it is combined with Probenecid.
RibostamycinCefotaxime may increase the nephrotoxic activities of Ribostamycin.
SpectinomycinCefotaxime may increase the nephrotoxic activities of Spectinomycin.
StreptomycinCefotaxime may increase the nephrotoxic activities of Streptomycin.
TobramycinCefotaxime may increase the nephrotoxic activities of Tobramycin.
WarfarinCefotaxime may increase the anticoagulant activities of Warfarin.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Pharmacological action
yes
Actions
inhibitor
General Function:
Transferase activity, transferring acyl groups
Specific Function:
Not Available
Gene Name:
pbp1b
Uniprot ID:
Q7CRA4
Molecular Weight:
89479.92 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [PubMed:7447421 ]
Kind
Protein
Organism
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Pharmacological action
yes
Actions
inhibitor
General Function:
Transferase activity, transferring acyl groups
Specific Function:
Not Available
Gene Name:
pbp2a
Uniprot ID:
Q8DNB6
Molecular Weight:
80797.94 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [PubMed:7447421 ]
Kind
Protein
Organism
Bacillus subtilis (strain 168)
Pharmacological action
yes
Actions
inhibitor
General Function:
Penicillin binding
Specific Function:
Not Available
Gene Name:
pbpC
Uniprot ID:
P42971
Molecular Weight:
74405.915 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Selakovitch-Chenu L, Seroude L, Sicard AM: The role of penicillin-binding protein 3 (PBP 3) in cefotaxime resistance in Streptococcus pneumoniae. Mol Gen Genet. 1993 May;239(1-2):77-80. [PubMed:8510666 ]
  4. Krauss J, Hakenbeck R: A mutation in the D,D-carboxypeptidase penicillin-binding protein 3 of Streptococcus pneumoniae contributes to cefotaxime resistance of the laboratory mutant C604. Antimicrob Agents Chemother. 1997 May;41(5):936-42. [PubMed:9145848 ]
  5. Georgopapadakou NH, Smith SA, Cimarusti CM, Sykes RB: Binding of monobactams to penicillin-binding proteins of Escherichia coli and Staphylococcus aureus: relation to antibacterial activity. Antimicrob Agents Chemother. 1983 Jan;23(1):98-104. [PubMed:6338822 ]
Kind
Protein
Organism
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Pharmacological action
yes
Actions
inhibitor
General Function:
Penicillin binding
Specific Function:
Cell wall formation.
Gene Name:
pbpA
Uniprot ID:
Q8DR59
Molecular Weight:
79700.9 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [PubMed:7447421 ]
Kind
Protein
Organism
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Pharmacological action
yes
Actions
inhibitor
General Function:
Penicillin binding
Specific Function:
Not Available
Gene Name:
penA
Uniprot ID:
P0A3M6
Molecular Weight:
73872.305 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [PubMed:7447421 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Takeda M, Babu E, Narikawa S, Endou H: Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol. 2002 Mar 8;438(3):137-42. [PubMed:11909604 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Takeda M, Babu E, Narikawa S, Endou H: Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol. 2002 Mar 8;438(3):137-42. [PubMed:11909604 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name:
SLC22A11
Uniprot ID:
Q9NSA0
Molecular Weight:
59970.945 Da
References
  1. Takeda M, Babu E, Narikawa S, Endou H: Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol. 2002 Mar 8;438(3):137-42. [PubMed:11909604 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Gene Name:
SLC22A7
Uniprot ID:
Q9Y694
Molecular Weight:
60025.025 Da
References
  1. Khamdang S, Takeda M, Babu E, Noshiro R, Onozato ML, Tojo A, Enomoto A, Huang XL, Narikawa S, Anzai N, Piyachaturawat P, Endou H: Interaction of human and rat organic anion transporter 2 with various cephalosporin antibiotics. Eur J Pharmacol. 2003 Mar 28;465(1-2):1-7. [PubMed:12650826 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [PubMed:15567297 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Baneres-Roquet F, Gualtieri M, Villain-Guillot P, Pugniere M, Leonetti JP: Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions. Antimicrob Agents Chemother. 2009 Apr;53(4):1528-31. doi: 10.1128/AAC.00971-08. Epub 2009 Jan 21. [PubMed:19164148 ]
Kind
Protein
Organism
Acinetobacter baumannii
Pharmacological action
unknown
General Function:
Beta-lactamase activity
Specific Function:
Not Available
Gene Name:
Not Available
Uniprot ID:
B2ZTR6
Molecular Weight:
40542.17 Da
References
  1. Rodriguez-Martinez JM, Nordmann P, Ronco E, Poirel L: Extended-spectrum cephalosporinase in Acinetobacter baumannii. Antimicrob Agents Chemother. 2010 Aug;54(8):3484-8. doi: 10.1128/AAC.00050-10. Epub 2010 Jun 14. [PubMed:20547808 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Peptide:proton symporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name:
SLC15A2
Uniprot ID:
Q16348
Molecular Weight:
81782.77 Da
References
  1. Pedretti A, De Luca L, Marconi C, Regazzoni L, Aldini G, Vistoli G: Fragmental modeling of hPepT2 and analysis of its binding features by docking studies and pharmacophore mapping. Bioorg Med Chem. 2011 Aug 1;19(15):4544-51. doi: 10.1016/j.bmc.2011.06.027. Epub 2011 Jun 16. [PubMed:21741846 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [PubMed:15567297 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Peptide:proton symporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name:
SLC15A2
Uniprot ID:
Q16348
Molecular Weight:
81782.77 Da
References
  1. Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [PubMed:15567297 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Takeda M, Babu E, Narikawa S, Endou H: Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol. 2002 Mar 8;438(3):137-42. [PubMed:11909604 ]
  2. Jung KY, Takeda M, Shimoda M, Narikawa S, Tojo A, Kim DK, Chairoungdua A, Choi BK, Kusuhara H, Sugiyama Y, Sekine T, Endou H: Involvement of rat organic anion transporter 3 (rOAT3) in cephaloridine-induced nephrotoxicity: in comparison with rOAT1. Life Sci. 2002 Mar 8;70(16):1861-74. [PubMed:12005172 ]
  3. Jariyawat S, Sekine T, Takeda M, Apiwattanakul N, Kanai Y, Sophasan S, Endou H: The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther. 1999 Aug;290(2):672-7. [PubMed:10411577 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Takeda M, Babu E, Narikawa S, Endou H: Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol. 2002 Mar 8;438(3):137-42. [PubMed:11909604 ]
  2. Jung KY, Takeda M, Shimoda M, Narikawa S, Tojo A, Kim DK, Chairoungdua A, Choi BK, Kusuhara H, Sugiyama Y, Sekine T, Endou H: Involvement of rat organic anion transporter 3 (rOAT3) in cephaloridine-induced nephrotoxicity: in comparison with rOAT1. Life Sci. 2002 Mar 8;70(16):1861-74. [PubMed:12005172 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name:
SLC22A11
Uniprot ID:
Q9NSA0
Molecular Weight:
59970.945 Da
References
  1. Takeda M, Babu E, Narikawa S, Endou H: Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol. 2002 Mar 8;438(3):137-42. [PubMed:11909604 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Gene Name:
SLC22A7
Uniprot ID:
Q9Y694
Molecular Weight:
60025.025 Da
References
  1. Khamdang S, Takeda M, Babu E, Noshiro R, Onozato ML, Tojo A, Enomoto A, Huang XL, Narikawa S, Anzai N, Piyachaturawat P, Endou H: Interaction of human and rat organic anion transporter 2 with various cephalosporin antibiotics. Eur J Pharmacol. 2003 Mar 28;465(1-2):1-7. [PubMed:12650826 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on February 21, 2014 11:46